Ute Jungwirth

Ute Jungwirth

Auto-generated profile, based on publicly available information

Ute Jungwirth

Department of Life Sciences, University of Bath, Bath, BA2 7AY, UK

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 August 2011 in Antioxidants & Redox Signaling
Verified
Journal Article
Closed access
UJUte Jungwirth
Ute Jungwirth
CKChristian Kowol
Christian Kowol
BKBernhard K. Keppler
Bernhard K. Keppler
CHChristian Hartinger
Christian Hartinger
Walter BergerWalter Berger
Walter Berger
PHPetra Heffeter
Petra Heffeter
Cells require tight regulation of the intracellular redox balance and consequently of reactive oxygen species for proper redox signaling and maintenance of metal ( e.g. , of iron and copper) homeostasis. In several diseases, including cancer, this balance is disturbed. Therefore, anticancer drugs targeting the redox systems, for example, glutathione and thioredoxin, have entered focus of interest. Anticancer metal complexes (platinum, gold, arsenic, ruthenium, rhodium, copper, vanadium, cobalt, manganese, gadolinium, and molybdenum) have been shown to strongly interact with or even disturb cellular redox homeostasis. In this context, especially the hypothesis of “activation by reduction” as well as the “hard and soft acids and bases” theory with respect to coordination of metal ions to cellular ligands represent important concepts to understand the molecular modes of action of anticancer metal drugs. The aim of this review is to highlight specific interactions of metal-based anticancer drugs with the cellular redox homeostasis and to explain this behavior by considering chemical properties of the respective anticancer metal complexes currently either in (pre)clinical development or in daily clinical routine in oncology. Antioxid. Redox Signal. 15, 1085–1127.

24 June 2022 in Cancer Research
Verified
Journal Article
Open access
PDF file
LJLiam Jenkins
Liam Jenkins
UJUte Jungwirth
Ute Jungwirth
AAAlexandra Avgustinova
Alexandra Avgustinova
MIMarjan Iravani
Marjan Iravani
AMAdam Mills
Adam Mills
CIClare M. Isacke
Clare M. Isacke
Immune-checkpoint blockade (ICB) promotes antitumor immune responses and can result in durable patient benefit. However, response rates in breast cancer patients remain modest, stimulating efforts to discover novel treatment options. Cancer-associated fibroblasts (CAF) represent a major component of the breast tumor microenvironment and have known immunosuppressive functions in addition to their well-established roles in directly promoting tumor growth and metastasis. Here we utilized paired syngeneic mouse mammary carcinoma models to show that CAF abundance is associated with insensitivity to combination αCTLA4 and αPD-L1 ICB. CAF-rich tumors exhibited an immunologically cold tumor microenvironment, with transcriptomic, flow cytometric, and quantitative histopathologic analyses demonstrating a relationship between CAF density and a CD8+ T-cell–excluded tumor phenotype. The CAF receptor Endo180 (Mrc2) is predominantly expressed on myofibroblastic CAFs, and its genetic deletion depleted a subset of αSMA-expressing CAFs and impaired tumor progression in vivo. The addition of wild-type, but not Endo180-deficient, CAFs in coimplantation studies restricted CD8+ T-cell intratumoral infiltration, and tumors in Endo180 knockout mice exhibited increased CD8+ T-cell infiltration and enhanced sensitivity to ICB compared with tumors in wild-type mice. Clinically, in a trial of melanoma patients, high MRC2 mRNA levels in tumors were associated with a poor response to αPD-1 therapy, highlighting the potential benefits of therapeutically targeting a specific CAF subpopulation in breast and other CAF-rich cancers to improve clinical responses to immunotherapy. Significance: Paired syngeneic models help unravel the interplay between CAF and tumor immune evasion, highlighting the benefits of targeting fibroblast subpopulations to improve clinical responses to immunotherapy.

1 February 2008 in Drug Resistance Updates
Verified
Journal Article
Closed access
PHPetra Heffeter
Petra Heffeter
UJUte Jungwirth
Ute Jungwirth
MJMichael A. Jakupec
Michael A. Jakupec
CHChristian Hartinger
Christian Hartinger
Mathea Sophia GalanskiMathea Sophia Galanski
Mathea Sophia Galanski
Walter BergerWalter Berger
Walter Berger

11 March 2010 in JBIC Journal of Biological Inorganic Chemistry
Verified
Journal Article
Closed access
PDF file
PHPetra Heffeter
Petra Heffeter
KBKatharina Böck
Katharina Böck
BABihter Atil
Bihter Atil
MHMir Ali Reza Hoda
Mir Ali Reza Hoda
WKWilfried Körner
Wilfried Körner
GKGunda Koellensperger
Gunda Koellensperger

6 March 2013 in Chemical Communications
Verified
Journal Article
Open access
PDF file
WKWolfgang Kandioller
Wolfgang Kandioller
EBEvelyn Balsano
Evelyn Balsano
SMSamuel M. Meier-Menches
Samuel M. Meier-Menches
UJUte Jungwirth
Ute Jungwirth
SGSimone Göschl
Simone Göschl
CHChristian Hartinger
Christian Hartinger
Organometallic RuII, OsII and RhIII complexes of lapachol induce apoptosis in human tumour cell lines in the low μM range by a mode of action involving oxidative stress, especially in the case of the ruthenium compound.

20 June 2019 in Nature Communications
Verified
Journal Article
Open access
PDF file
AWAntoinette van Weverwijk
Antoinette van Weverwijk
NKNikolaos Koundouros
Nikolaos Koundouros
MIMarjan Iravani
Marjan Iravani
MAMatthew Ashenden
Matthew Ashenden
QGQiong Gao
Qiong Gao
CIClare M. Isacke
Clare M. Isacke
The different stages of the metastatic cascade present distinct metabolic challenges to tumour cells and an altered tumour metabolism associated with successful metastatic colonisation provides a therapeutic vulnerability in disseminated disease. We identify the aldo-keto reductase AKR1B10 as a metastasis enhancer that has little impact on primary tumour growth or dissemination but promotes effective tumour growth in secondary sites and, in human disease, is associated with an increased risk of distant metastatic relapse. AKR1B10High tumour cells have reduced glycolytic capacity and dependency on glucose as fuel source but increased utilisation of fatty acid oxidation. Conversely, in both 3D tumour spheroid assays and in vivo metastasis assays, inhibition of fatty acid oxidation blocks AKR1B10High-enhanced metastatic colonisation with no impact on AKR1B10Low cells. Finally, mechanistic analysis supports a model in which AKR1B10 serves to limit the toxic side effects of oxidative stress thereby sustaining fatty acid oxidation in metabolically challenging metastatic environments.